Skip to content Skip to sidebar Skip to footer

All Posts

HomeAll Posts
November 15, 2025

Merck Mixes Up Its Pipeline With Cidara $9.2B Acquisition—GeoVax Keeps Driving Towards Value in the Vaccine Lane -( $MRK $CDTX $GOVX $IBB )

Merck (MRK), ever the discerning giant of Big Pharma, has decided to join the prophylactic party by acquiring Cidara Therapeutics (CDTX) for a headline-grabbing $9.2 billion—a move that whispers both “strategic pipeline expansion” and “Keytruda’s patent clock is ticking, folks.” In a deal that more than doubled Cidara’s share price overnight, Merck will pay $221.50 per share, an eye-watering 109% premium, and add not just Cidara’s cash-burning potential but also its promising experimental flu drug, CD388, to its infectious disease portfolio.

Merck’s Bet: From Patent Cliff to Flu Cliff

Why toss $9.2 billion into Cidara’s collection plate? Merck is bracing for the revenue cliff as Keytruda, the reigning king of PD-1 inhibitors, closes in on its patent expiry date, while Gardasil faces an increasingly crowded market. Enter CD388, Cidara’s late-phase, long-acting antiviral intended not just for the typical “high-risk” crowd, but potentially broad swaths of healthy adults as well. It’s a shrewd response to a world hungry for pandemic insurance, and Wall Street analysts such as Cantor’s Carter Gould are already forecasting the kind of sales that might help offset incoming patent cliffs.

Notably, Merck couldn’t resist a biotech bidding war rumor, with whispers that at least one rival was eyeing Cidara, proving that even in biopharma M&A, timing is everything—assuming the ability to pay a 100% premium is considered timing and not just bravado.

Meanwhile, at GeoVax: Quietly Advancing the Vaccine Frontier

While Merck and Cidara dance under the M&A limelight, GeoVax Labs (GOVX), that other perennial contender in biotech’s vaccine ring, continues to rack up clinical progress and headline-neutralizing data. GeoVax recently updated the world on its Phase 2 clinical trials for GEO-CM04S1—a next-generation, dual-antigen COVID-19 vaccine aimed at the unusually under-served group of immunocompromised cancer patients. Interim data show not only enhanced T-cell immunity and robust antibody responses in blood cancer and CLL cohorts, but also a safety profile that’s outshining standard mRNA offerings. So impressive, in fact, that the mRNA comparator arm of its CLL trial was axed for futility, leaving GeoVax’s vaccine standing tall.

Never one to leave a regulatory update on the table, GeoVax is also pushing its GEO-MVA vaccine for Mpox and smallpox toward a streamlined Phase 3 clinical trial, skipping the traditional trial phases altogether thanks to recent European regulatory guidance. The company touts a healthy intellectual property portfolio, fresh EMA milestones, and a focus on needle-free, self-administered vaccines via microarray patches. Bioprogress, but with a side of creative delivery.

A Final Word: Old School M&A, New School Science

As Merck and Cidara’s big-dollar deal reminds the sector that megadeals can still get done at double-the-market prices, GeoVax (GOVX) soldiers on in the trenches, one immunogenicity endpoint at a time. Investors—and the science-inclined—can thus enjoy a pharmaceutical market teetering between splashy headlines and the quieter, unflashy progress that sometimes changes the course of global health. In this climate, never underestimate either the power of a corporate checkbook or a well-powered Phase 2 trial.

The Sources…

  1. https://www.merck.com/news/merck-to-acquire-cidara-therapeutics-inc-diversifying-its-portfolio-to-include-late-phase-antiviral-agent/
  2. https://www.reuters.com/legal/litigation/merck-bets-flu-prevention-with-about-92-billion-deal-cidara-therapeutics-2025-11-14/
  3. https://www.cooley.com/news/coverage/2025/2025-11-14-cidara-therapeutics-to-be-acquired-by-merck
  4. https://www.biopharmadive.com/news/merck-cidara-acquire-flu-antiviral-drug/805513/
  5. https://www.morningstar.com/news/marketwatch/20251114178/this-is-why-merck-is-buying-cidara-therapeutics-for-92-billion-and-why-wall-street-is-happy
  6. https://www.investors.com/news/technology/cidara-therapeutics-stock-merck-takeover/
  7. https://www.fiercebiotech.com/biotech/merck-co-pays-92b-owner-influenza-antiviral-janssen-rejected
  8. https://www.geovax.com/investors/press-releases/geovax-recognizes-world-immunization-day-advancing-innovation-and-trust-in-vaccination
  9. https://www.geovax.com/investors/press-releases/geovax-reports-third-quarter-2025-financial-results-and-provides-business-update
  10. https://finance.yahoo.com/news/geovax-reports-third-quarter-2025-210000454.html
  11. https://geovax.com/geovax-news
  12. https://www.cnbc.com/2025/11/14/merck-to-acquire-cidara-therapeutics.html
  13. https://www.statnews.com/2025/11/14/merck-acquire-cidara-therapeutics-influenza-prevention/
  14. https://www.cnbc.com/quotes/GOVX
  15. https://finance.yahoo.com/news/merck-acquire-cidara-therapeutics-inc-114500346.html
  16. https://www.geovax.com/investors/press-releases
  17. https://www.geovax.com
  18. https://www.investing.com/news/transcripts/earnings-call-transcript-geovax-q3-2025-shows-revenue-decline-stock-dips-93CH-4357363
  19. https://seekingalpha.com/news/4522063-geovax-outlines-expedited-geo-mva-clinical-trial-and-global-partnership-strategy-for
November 14, 2025

Wall Street’s Cha-Cha: Shutdowns, Surges, and Market Shenanigans—Weekly Market Wrap, Nov. 14, 2025 -( $AAPL $CDTX $EPRX $LLY $MCD $MODD $MRK $MTWO $NVDA $OPEN $RIO $SER $WHSP Rise!)

If scorekeepers gave points for wit, this week would earn an honorable mention—showcasing the market’s ability to sprint, stumble, and get up again before anyone starts playing the national anthem. Investors, however, are left pondering what comes next, armed with quarterly reports, delayed macro data, and a fresh appreciation for the market’s sense of mischief. Yes indeed as Wall Street’s week came to a close like a well-matured cabernet—complex, a little tart on Thursday’s downswing, but still adding a dash of optimism for those with a taste for macroeconomic uncertainty and tech-sector volatility. For those who prefer their numbers shaken, not stirred, here’s the latest market wrap for the week ending Friday, November 14, 2025.

Equity Index Performance

The S&P 500 eked out a fractional gain, holding onto record territory after a Thursday stumble, and finishing at 6,734.11 for a nearly flat week. The Dow Jones Industrial Average weathered a bumpier ride, slipping 0.7% Friday but still settling up 0.3% for the week, bravely defending its recent foray above 48,000. The Nasdaq Composite, however, couldn’t outpace the high-speed turbulence in tech, ending 0.5% lower for the week—prompting some traders to wonder if artificial intelligence might one day program a less temperamental index. Small caps, represented by the Russell 2000, finished lower as investors donned defensive hats and ducked for cover amid broader risk aversion. but many bids were found on Friday, especially in the biotech sector that swing significantly.

Macroeconomic Reports & US Shutdown Update

Investors hoping for a feast of government economic data found the table a little bare, thanks to the longest shutdown in US history—43 days and counting—a streak that left key figures like CPI, Retail Sales, and the October jobs report languishing in limbo. Private-sector data helped fill the gaps: global manufacturing edged up, though contraction persisted in big economies like Japan and Taiwan, while US consumer debt grew at a 3.1% annual rate and small business optimism inched lower. With shutdowns easing but data delays in the forecast, analysts are bracing for belated government releases, possibly weighed down by more caveats than a Wall Street prospectus.

Company Highlights

  • Eli Lilly (LLY, $1,025, +10.92% over the last 5-days): The pharmaceutical giant found itself in the buy zone, riding positive sentiment as investor enthusiasm for healthcare stocks continued.
  • Taiwan Semiconductor Manufacturing (TSMC, $284.82, -.59% over the last 5-days): TSMC kept its chip fabrication running at capacity, with reports of scaling efforts to aid growth-hungry AI players like Nvidia and Tesla.
  • Nvidia (NVDA, $190.17, +1.07% over the last 5-days): After a Monday rally, Nvidia fell victim to a tech-sector sell-off midweek, as US blocks on certain chip sales to China raised fresh regulatory hurdles.
  • Apple (AAPL, $272.41, +1.47% over the last 5-days): Apple weathered volatility with little news splash; traders continue to monitor its supply chain and AI investments.
  • Tesla (TSLA, $404.35, -5.86% over the last 5-days): CEO Elon Musk hinted at a possible “mega AI chip fab” and mused about a possible Intel collaboration, fueling speculation but no signed deals yet.
  • Broadcom (AVGO, $342.46, -1.99% over the last 5-days): Still riding high on AI optimism, Broadcom seemed to quietly sidestepped the chip-sector noise.
  • Meta (META, $609.46, -1.97% over last 5-days): Meta got caught in the AI downdraft; its stock declined as investors grew wary of tech valuations.
  • Nokia (NOK, $6.73,-1.61% over the last 5-days): Nokia kept a lower profile, with its European peers seeing muted action.
  • McDonald’s (MCD, $307.03, +2.46% over the last 5-days): Digesting steady global sales data, McDonald’s shares remained largely resilient in a defensive sector week.
  • Rio Tinto (RIO,$70.63, +1.88% over the last 5-days): The miner swept up positive resource news, tracking higher commodity prices.
  • Oracle (ORCL, $222.85, -6.86% overt he last 5-days): Oracle joined the downward parade with its fellow tech heavyweights, reflecting the sector’s broader malaise, but rebounded a bit on Friday.
  • Intel (INTC, $35.52, -6.85% over the last 5-days): Potential AI ambitions and chip partnership chatter (thank you, Tesla) kept the rumor mill buzzing, but it nonetheless recoiled significantly this week.
  • OKLO (OKLO, $97.57, -13.39% over the last 5-days): Low-volume chatter on energy storage startups suggests investors still have an appetite for alternative energy, but OKLO chunked down double digits this week.
  • Opendoor (OPEN): Shares jumped 23.78% over the last 5-days.
  • Palantir Technologies (PLTR, $174.20, -2.20% over the last 5-days): Led an AI surge Monday, but saw profit-taking as tech momentum waned.

Mergers, Acquisitions, and Buyouts

Dealmakers found reason to toast: Merck (MRK, $92.92, +7.70% over the last 5-days) acquired Cidara Therapeutics (CDTX, $217.71, +108.55% over the last 5-days) in a $9.2 billion bet on experimental flu prevention, and Lundbeck lobbed a disruptive $2.25 billion bid for Avadel Pharmaceuticals (AVDL, $23.56, +26.06% over the last 5-days). Postman’s API platform vision accelerated with the acquisition of liblab, though most headlines tracked big pharma’s moves as sector standouts.

IPOs

IPOs remained robust, with WeShop Holdings making its direct listing Nasdaq debut under ticker “WSHP,” joining a cohort that has pushed US IPO totals for 2025 nearly 62% higher year-over-year. WHSP share jumped 50.90%. Several filings are still working through delayed data, but overall, the new listing pace remains brisk.

Tariffs and Trade Updates

Tariff talk popped up as AI chip exports to China received fresh restrictions, sparking sales declines at NVIDIA and other tech majors. No new broad-based US import tariff actions were announced this week.

Yield Curve, Interest Rates & FOMC

Bond yields staged a retreat after shutdown resolution, with the 10-year Treasury falling to 4.07% (down 9 basis points), while the 2-year landed at 3.57%. Rate-cut odds for December fell from near-certainty (95%) in October to a coin toss at 50%, courtesy of hawkish Fed remarks and data delays. The next critical FOMC signals and meeting minutes are expected in the coming week, pending data resumption.

Commodities: Gold, Silver, Oil & Bitcoin

Gold staged a volatile show: briefly surging above $4,200/oz before ending at $4,084.40 and stunningly 59.04% higher year-over-year. Silver mirrored these moves, retreating to $50.40/oz, up 65.20% YoY. Oil rebounded to $59.95/bbl, up modestly for the week amid supply hiccups, while OPEC’s 2026 outlook weighed on futures. Bitcoin tumbled below $100,000, trading near $95,266.32 Friday afternoon, suffering in the risk-off sweep that seized equities and crypto markets alike.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.5333, +2.56% over the last 5-days), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.56, +20.37% over the last 5-days), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated, “These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.4511), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, reported (Nov. 13) its financial results for the quarter ended September 30, 2025, and provided a business update highlighting key corporate and clinical advancements across its vaccine and oncology programs. David Dodd, CEO of Geovax stated, “As highlighted in this report, during the third quarter GeoVax continued making important progress, advancing innovative vaccines and immunotherapies that address urgent and underserved medical needs. With continued global Mpox spread and constrained vaccine supply, our GEO-MVA program represents a U.S.-based, scalable, next-generation MVA platform. Our EMA and BARDA-aligned program position GeoVax to accelerate regulatory readiness and commercial entry. For our GEO-CM04S1 COVID-19 vaccine program, recent clinical presentations validate our belief that multi-antigen vaccines – expressing both spike and nucleocapsid – are essential for breadth and durability in vulnerable immunocompromised populations. In particular, the robust immune responses demonstrated in Chronic Lymphocytic Leukemia (CLL) patients represents a meaningful step forward in addressing the unmet needs of over 40 million immunocompromised Americans. In our Gedeptin(R) oncology program, the expansion into multiple solid tumor indications builds upon a growing recognition that tumor-targeted immune priming can dramatically improve checkpoint outcomes. We are executing a clear path to clinical and commercial value creation. GeoVax continues to execute with purpose and discipline. Our multi-antigen vaccine and immunotherapy platforms position the Company squarely within the national call to strengthen America’s health security, expand domestic manufacturing, and deliver equitable global solutions.”

Volato Group, Inc. (NYSE American: SOAR, $1.35) and M2i Global, Inc. (MTWO, $.10, +.0.00%) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $4.09, +4.60% over the last 5-days ) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s diseas. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $34.24) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

https://finance.yahoo.com/quote/SI=F/history/

https://www.marketwatch.com/livecoverage/stock-market-today-dow-s-p-500-and-nasdaq-set-for-more-selling-bitcoin-trades-below-100-000

https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaqa-nvda-nvidia-stock-tesla-tsla-stock/

https://uk.finance.yahoo.com/news/major-us-stock-indexes-fared-212222093.html

https://www.stl.news/global-markets-turn-defensive-overnight-nov-14-2025/

https://www.youtube.com/watch?v=4x6gZLdVwg4

https://www.reuters.com/business/us-stock-futures-rise-hopes-end-government-shutdown-2025-11-10/

https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-palantir-eli-lilly-buy-zones/

https://www.americanchemistry.com/chemistry-in-america/news-trends/weekly-economic-report/2025/weekly-chemistry-and-economic-trends-11-14-25

https://www.chandlerasset.com/insights/11/14/25-government-shutdown-ends-market-uncertainty-continues?hsLang=en

https://www.cnbc.com/2025/11/14/heres-where-things-stand-on-when-the-government-will-start-releasing-key-economic-reports.html

https://www.cnn.com/2025/11/14/economy/federal-data-what-to-expect-economic-data

https://finance.yahoo.com/news/high-growth-tech-stocks-watch-093826107.html

https://www.nytimes.com/2025/11/14/business/economy-data-shutdown.html

https://www.nasdaq.com/articles/5-top-artificial-intelligence-ai-stocks-buy-november

https://www.reuters.com/legal/litigation/merck-bets-flu-prevention-with-about-92-billion-deal-cidara-therapeutics-2025-11-14/

https://www.businesswire.com/newsroom/subject/merger-acquisition

https://www.fiercepharma.com/pharma/lundbeck-disrupts-alkermes-planned-21b-purchase-avadel-higher-bid

https://stockanalysis.com/actions/acquisitions/2025/

https://www.themiddlemarket.com/latest-news/merck-purchases-cidara-therapeutics-in-9-2b-deal

https://www.biospace.com/business/pfizer-reportedly-planning-to-divest-biontech-stake

https://www.iposcoop.com/ipos-recently-filed/

https://finance.yahoo.com/calendar/ipo/

https://stockanalysis.com/ipos/2025/

https://www.incomeresearch.com/weekly-fixed-income-market-update-november-13-2025/

https://www.federalreserve.gov/releases/h15/

https://www.reuters.com/business/us-10-year-treasury-yields-priced-no-inflation-surprises-set-rise-modestly-2025-11-13/

https://global.morningstar.com/en-nd/markets/december-us-fed-interest-rate-cut-is-now-coin-toss

https://tradingeconomics.com/commodity/gold

https://www.usagold.com/daily-gold-price-history/

https://www.marketwatch.com/investing/future/gcx25

https://www.wsj.com/market-data/quotes/futures/SIX25

https://www.economies.com/crypto/news/bitcoin-tumbles-to-$97,000-amid-a-global-selloff-wave..-whats-happening%20-47749

https://www.usagold.com/daily-silver-price-history/

https://tradingeconomics.com/commodity/crude-oil

https://fortune.com/article/current-price-of-silver-11-14-2025/

https://tradingeconomics.com/commodity/silver

https://www.investing.com/crypto/bitcoin/historical-data

https://finance.yahoo.com/quote/BTC-USD/history/

https://www.forbes.com/advisor/investing/gold-price/

https://www.investopedia.com/dow-jones-today-11122025-11847653

https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-14-2025

https://www.morningstar.com/news/marketwatch/20251114161/wall-streets-on-edge-these-are-the-levels-that-stocks-must-not-violate-says-fundstrat

https://www.jhinvestments.com/weekly-market-recap

https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-14-2025/card/heard-on-the-street-thursday-recap-seeing-red-ho2e3Ow3VPz3mlwwl947

https://www.cnn.com/markets

https://www.benzinga.com/calendars/m-a

https://dealroom.net/blog/upcoming-m-a

https://www.nasdaq.com/market-activity/ipos

https://www.wsj.com/business/deals

https://www.nyse.com/ipo-center/filings

https://www.clevelandfed.org/indicators-and-data/yield-curve-and-predicted-gdp-growth

https://intellizence.com/insights/merger-acquisition/

https://www.isabullion.com/reports/daily-gold-and-silver-market-analysis-14-november-2025/

https://goldprice.org

https://www.dailyforex.com/forex-technical-analysis/2025/11/gold-forecast-14-november-2025/237005

https://finance.yahoo.com/quote/GC=F/history/

https://www.kitco.com/news/article/2025-11-14/gold-market-analysis-november-14-key-intra-day-price-entry-levels-active

https://www.forexfactory.com/news/1371118-gold-price-falls-3-amid-market-selloff

November 14, 2025

Modular Medical’s Tubeless Insulin Patch Pump Races Toward FDA Review: Can Simplicity Dominate a $3 Billion Market? -( $MODD )

Modular Medical (NASDAQ: MODD) recently ramped up the news cycle with a flurry of regulatory milestones, engineering feats, and even a bit of C-suite global musical chairs—all tailored to make insulin delivery as easy as changing your socks (and almost as affordable).

Modular’s Latest Feats: FDA Race Initiated Post Shutdown

Modular Medical’s engineers just fired the starting gun on the FDA clearance race by submitting their next-generation Pivot tubeless insulin patch pump for 510(k) review as of this morning, November 14, 2025. The device, a “can’t-believe-it’s-not-wearable” patch, sports a 3ml removable reservoir and a detachable design. It seems to be perfect for adults who want to ditch hoses and controllers and finally shower—pump-free—without risking market volatility or their dignity. Jeb Besser, CEO of Modular Medical stated “The Pivot submission is an exciting milestone in our mission to deliver a differentiated tubeless patch pump experience to those who want a simple pump to manage the treatment of diabetes. Our Pivot patch pump offers a 3 ml reservoir, the flexibility of removing the pump and the ability to bolus without a separate controller, all without sacrificing the accuracy, communications and clinical reporting advantages of a true electronic pump. Convincing a person who requires daily insulin to adopt a pump, instead of multiple daily injections, can improve the patient and clinical experience, while potentially reducing healthcare costs and improving long-term patient outcomes. We believe our two-part Pivot patch pump design, easy to learn interface and scalable manufacturing will all contribute to a differentiated user experience and represents a unique approach to this market. On behalf of the board of directors, I would like to thank the entire Modular Medical team, and all of our stakeholders and shareholders for their support to allow us to achieve this major milestone. With the end of the U.S. government shutdown, we have now been able to submit the Pivot for 510(k) clearance to the FDA. We expect to receive initial questions from the FDA this quarter and are proceeding in parallel with the manufacturing preparation to be able to commercially launch our Pivot product upon clearance.”

A Grand Vision, or Just Patchwork?

Not only does Modular Medical claim the Pivot’s design is as simple as a Wall Street bonus structure, it’s going after the “almost-pumpers”—an untapped $3 billion diabetes market segment. The company teases a Q1 2026 commercial launch “upon clearance,” with the necessary disclaimer that FDA reviewers, like Wall Street analysts, are unpredictable.

Production: From Factory Floor to Patient Door

In a manufacturing triumph, Pivot cartridges controller validation was completed. Modular’s team boasted that this milestone “derisks” the path to commercialization. The rigorous process included a Stage 1 ISO 13485:2016 audit with no major nonconformances, an achievement that would make even an SEC examiner smile, or at least raise an eyebrow.

International Moves and Boardroom Shuffles

The company appointed David Bosshard as the new head of international operations, aiming to make Pivot a globe-trotter after charming regulators abroad. Management also touted ongoing progress toward a CE Mark for European entry, planning further audits through 2026. Rumor has it, if the Pivot pump could post on Instagram, it’d be hashtagging “#globalsupplychain”.

Clinical and Real-World Trials: Field-Tested by Docs

MODD’s clinical studies included real-world usage by nine savvy clinicians with Type 1 diabetes. Their feedback is fueling final tweaks before the big Pivot launch. Plus, a new IRB-approved feasibility study is set to test extended wear performance, because even pumps deserve a spa day.

Financing the Future

Behind every headline is a cash register: Modular Medical recently scored gross proceeds of ~$4.4M from the exercise of the Existing Warrants. Investors, clearly believers in patchwork solutions, see the potential to shake up a market used to patchy outcomes.

The Sum…

With diabetes prevalence rising globally, the Company believes it is well positioned to capture significant market share through its innovative patch pump technology. If Modular Medical succeeds, it might just give diabetes care a much-needed injection of simplicity—and the boardroom some reason to break out the (diet) champagne. In the meantime, MODD’s press office is believed to be keeping the insulin (and the news) flowing.

The Sources

  1. https://finance.yahoo.com/news/modular-medical-submits-pivot-tubeless-140000932.html
  2. https://www.morningstar.com/news/accesswire/1102238msn/modular-medical-submits-pivot-tubeless-insulin-patch-pump-for-fda-510k-clearance
  3. https://www.nasdaq.com/press-release/modular-medical-announces-ongoing-progress-obtain-ce-mark-2025-10-28
  4. https://www.drugdeliverybusiness.com/modular-medical-new-head-international-operations/
  5. https://www.biospace.com/press-releases/modular-medical-receives-irb-approval-for-pivot-insulin-delivery-system-feasibility-study
  6. https://www.biospace.com/press-releases/modular-medical-announces-completion-of-clinical-study-of-modd1-pump
  7. https://markets.financialcontent.com/stocks.theolympian/quote/news?CurrentPage=1&Symbol=NQ%3AMODD
  8. https://www.nasdaq.com/market-activity/stocks/modd/press-releases
  9. https://finance.yahoo.com/quote/MODD/press-releases/
  10. https://seekingalpha.com/symbol/MODD/press-releases
  11. https://uk.investing.com/news/company-news/modular-medical-submits-fda-application-for-tubeless-insulin-patch-pump-93CH-4372237
  12. https://money.tmx.com/en/quote/MODD:US/news
  13. https://ir.modular-medical.com/press-releases.php
  14. https://www.otcmarkets.com/stock/MODD/news/Modular-Medical-Appoints-David-Bosshard-to-Lead-its-International-Expansion-for-the-Pivot-Insulin-Delivery-System?e&id=3325150
  15. https://www.otcmarkets.com/stock/MODD/news/Modular-Medical-Announces-Ongoing-Progress-to-Obtain-CE-Mark?e&id=3340736
  16. https://www.cnbc.com/quotes/MODD
November 14, 2025

Eupraxia Bets on Durable Signals as Pipeline Optionality Grows

In a biotech climate where milestones arrive with the precision of a quarterly forecast and often carry as much suspense as a regulatory ruling, Eupraxia Pharmaceuticals (NASDAQ: EPRX) unveiled (after the close on Nov. 13) new 52-week follow-up data from its RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis. The company framed the update as reinforcing a longer-horizon narrative for its Diffusphere delivery platform, a technology touted as a potential differentiator in a crowded GI space. The message to investors is clear: durability matters as much as peak efficacy, and the long arc of patient outcomes increasingly informs capital allocation decisions.

Data and Implications

The 52-week readout adds to Eupraxia’s storyline around a targeted, local delivery approach designed to improve tolerability and adherence in chronic GI conditions. While headlines focus on durability, analysts will scrutinize endpoints, patient quality-of-life metrics, and safety signals that could justify continued investment in pivotal studies. In a market where a single data point can swing sentiment, Eupraxia’s emphasis on long-term durability signals a strategic preference for therapies that patients can realistically maintain over years rather than months. The company also frames the results as potential indicators of broader pipeline value if the Diffusphere platform translates beyond EoE into other inflammatory indications.

Market Context and Optionality

The EoE landscape remains competitive, with multiple programs racing to demonstrate persistent benefit with acceptable safety profiles. Eupraxia’s narrative hinges on a differentiated delivery technology that could address a key payer and patient concern: long-term convenience and tolerability. By underscoring pipeline optionality, the company suggests that RESOLVE data could support broader development discussions, including potential partnerships or strategic financing to accelerate late-stage programs if the path to pivotal studies encounters delays or regulatory hurdles.

Analyst Perspectives and Financing

Analysts are likely to weigh the durability signals against the overall risk profile typical of early- to mid-stage biotech programs. While positive, the 52-week data must be interpreted within the framework of regulatory timing, trial design considerations, and the economics of delivering a differentiated therapy. Currently analysts have ~$12 price targets for Eupraxia’s stock that closed at $6.34 on Thursday and is up +123.24% over the last year. Furthermore, Eupraxia’s messaging around the platform’s potential to support additional indications could help extend the company’s narrative beyond a single asset, a point of particular interest to investors seeking portfolio leverage in a crowded biotech market. On Nov. 4, Eupraxia confirmed that the Company had cash of $89.0 million as of September 30, 2025, up from $33.1 million at the end of the fourth quarter of 2024. These funds are reportedly being used to fund clinical trials in EP-104 and the remainder of the funds will be used for general and administrative expenses, working capital needs and other general corporate purposes. The Company anticipates that existing cash reserves, and proceeds from the anticipated future exercise of in-the-money warrants, will be sufficient to fund the Company into the first half of 2028.

Strategic Outlook

Looking ahead, Eupraxia’s priorities likely center on refining the clinical development plan for EP-104GI, advancing discussions with potential partners, and outlining a clear path to pivotal trials if the data continue to meet or exceed expectations. The Diffusphere platform could become a central strategic pillar, not only for EP-104GI but possibly for future assets in the pipeline, should the company secure the necessary funding and regulatory clarity to expand its footprint. In the current market, a durable update can serve as a tangible milestone around which management can frame near-term financing conversations and long-run value creation.

Conclusion

In biotech storytelling, promising early data must be tethered to a credible path to market. Eupraxia’s 52-week follow-up data for EP-104GI in EoE reinforces the core thesis: durability matters, and the Diffusphere platform could offer meaningful differentiation in a competitive field. If subsequent trials validate these signals and the company secures the strategic partnerships or financing needed to accelerate development, Eupraxia could move from a narrative of potential to a dated, disciplined plan for value creation in a sector where timelines are as important as the science.

The Sources

  1. https://sfcollege.libguides.com/database-citing/wsj
  2. https://guides.library.illinois.edu/citingadsources/wallstreetjournal
  3. https://blogs.ischool.berkeley.edu/i265s16/2016/04/15/gestalt-principles-and-affordances-on-wsj-com/
  4. https://www.up.edu/marketing/writing-style-guide/titles.html
  5. https://www.wsj.com/articles/vol-34-no-4-headlines-11620943687
  6. https://askus.baker.edu/faq/217644
  7. https://library.ctstate.edu/middlesex/wsj/cite
  8. https://financialpost.com/globe-newswire/eupraxia-pharmaceuticals-reports-additional-52-week-follow-up-data-from-the-resolve-trial-in-eosinophilic-esophagitis-eoe-demonstrating-consistent-results-after-dosing-with-ep-104gi
  9. https://www.stocktitan.net/news/EPRX/eupraxia-pharmaceuticals-reports-additional-52-week-follow-up-data-v79ulfurfkey.html
  10. https://www.investing.com/news/company-news/eupraxia-reports-durable-52week-results-for-eoe-treatment-93CH-4357222
  11. https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-promising-52-week-data-for-eoe-treatment
  12. https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corporate-update-302140476.html
November 13, 2025

The Golden Arches That Never Close -( $MCD $SPY $DIA )

The opening bell rings as McDonald’s (MCD) steps onto the trading floor with the quiet confidence of a long-tenured heavyweight. This quarter isn’t a fireworks show; it’s a well-tuned engine: disciplined pricing, reliable traffic, and a franchise framework that stays resilient even when the macro weather turns gusty. The street reads the tape with the steadiness of a timeless thesis: durability beats novelty in markets that crave certainty.

Same-store sales and regional momentum

  • U.S. performance: U.S. same-store sales rose 2.4%, helped by value-oriented promotions and the relaunch of Snack Wraps alongside Extra Value Meals. This lane-change in pricing and promotions kept the check size up while foot traffic remained supportive in key pounds-for-pennies markets. The performance in the United States anchors the quarter’s narrative as a proof of the brand’s affordability story working in practice.​
  • Global footprint: Global comparable sales advanced 3.6%, signaling broad-based momentum across regions even as inflation cooled consumer budgets differently around the world. International markets contributed to a diversified growth thrust that reduces reliance on any single geography. Systemwide sales posted a solid expansion, underscoring the scale advantages that support steady cash generation.​
  • Regional nuance: International Operated Markets and International Developmental Licensed Markets grew in the mid-to-high single digits, translating to a broader base of revenue streams and a resilience buffer against localized pressures. This regional tilt matters for investors who model long-run margin resilience and unit growth as part of the core thesis.​

Margins and profitability

  • Consolidated revenues rose modestly, reflecting a mix of volume, pricing discipline, and cost management. The margin narrative remains anchored by operating efficiency and the lever of capital allocation—invest where returns are strongest while maintaining a steady cash flow profile. In the context of rising or volatile input costs, the ability to preserve operating income growth signals the strength of McDonald’s operating system.​
  • Operating income and earnings per share (EPS) showed positive momentum, supported by pricing power and a disciplined cost stance. The company also noted pre-tax charges tied to restructuring in some quarters, a factor investors weigh against the ongoing top-line growth story when assessing long-run profitability.​

Cash flow, capital allocation, and loyalty dynamics

  • Systemwide and loyalty-related metrics illustrate the depth of the brand’s reach: loyalty-member purchases contribute a meaningful share of the quarter’s revenue pool, signaling the effectiveness of marketing and loyalty promotions in sustaining buycycles. This dynamic matters for cash flow quality and for evaluating the durability of the company’s returns profile.​
  • Free cash flow and the pace of share repurchase or dividend activity continue to be a focal point for investors seeking steady yield and margin of safety in a market environment that prizes capital discipline. The quarter’s cash-generation strength reinforces McDonald’s reputation for prudent allocation over speculative expansion.​

Strategic takeaways and market sentiment

  • The quarter reinforces a durable thesis: McDonald’s can deliver value-oriented growth through a combination of menu innovation, value messaging, and international diversification, all while maintaining a steady, capital-light model for cash generation. In a market where headline risk can outsize fundamentals, the company’s track record of consistent performance and strategic agility remains a compelling narrative for patient capital.​
  • Going forward, investors will likely monitor the pace of global systemwide sales growth, any shifts in pricing strategy, and ongoing investments that affect throughput and margins. The balance of value for customers and efficiency for the enterprise will continue to define the stock’s risk-reward profile.​

The Sources

November 13, 2025

Risk-Off Rhythm & Volatility Returns: S&P 500 Slips as Tech Giants Weigh on the Tape – Nov. 13, 2025 -( $LLY $MCD $META $VIX Rise!)

Equities ended the session notably weaker after a volatile day characterized by renewed selling in tech and high-growth names. Major indices closed lower, with the Nasdaq Composite leading declines among the big three benchmarks. The day’s moves underscored a shift in risk sentiment as rate-cut expectations waver and investors digest policymakers’ signals about monetary policy in an uncertain growth environment. The markets ‘fear gauge’, the CBOE Volatility Index (VIX) popped up 14.22% to $20.00.

Key indices

  • S&P 500 (6,737.49, -1.66%): The broad equity gauge slid, reflecting broad-based pressure across sectors, especially momentum-driven groups. The close was decisively negative on the day, highlighting a risk-off tilt among investors seeking shelter in less volatile corners of the market.
  • Nasdaq Composite (22,879.36, -2.29%): Tech-focused index suffered the steepest drop as many of the megacap and high-valuation names faced selling pressure. The breadth of losses pointed to a rotation away from growth and into more traditional sectors or cash-equivalents.
  • Dow Jones Industrial Average (47,457.22, -1.65%): The Dow also traded lower but remained supported by durable, dividend-yielding names and select industrials. The decline in the Dow was pronounced but somewhat tempered by a handful of leadership stocks in other corners of the market.

Sector and stock notes

  • Technology and communication services bore the brunt of selling, consistent with a renewed focus on higher discount rates and slower earnings upgrades for growth-centric names. The weakness was broad rather than isolated to a few names, signaling a systemic reassessment of risk.
  • Broad-market leadership in recent sessions—often driven by megacaps—reversed, underscoring that the market is not simply chasing the latest momentum but weighing a potential pivot in the Fed trajectory and macro guidance.
  • Notable price action around legacy high-beta names and AI/semiconductor-related plays, which had previously been crowd favorites, reflected a shift in expectations about near-term catalysts and policy support.

Macro context

  • Traders continued to price in a slower pace of rate reductions, or even the risk of a delayed easing cycle, given ongoing economic data and Federal Reserve commentary. The result was a more cautious stance toward equities, particularly those with rich valuations or sensitivity to interest rates. The 2-yr treasury closed up at 3.603% as did the 10-yr at 4.126%.
  • The sentiment backdrop remained nuanced: while some pockets of the market still attract strategic buyers on pullbacks, the broader risk tolerance has yet to fully recover, pending clarity on inflation dynamics and rate path.

What this means for investors

  • A lower-risk posture may persist in the near term, with emphasis on high-quality, defensively oriented names and cash-like liquidity until macro signals become clearer.
  • For traders, swift, disciplined risk controls and clearly defined levels of entry and exit remain crucial, given the potential for continued volatility around policy expectations and macro data flows.

Tech Titans: AMD, NVIDIA, Broadcom, Intel, Oracle

  • AMD (AMD): Shares slid 4.2% to $247.96, retreating from recent highs as investors digested the company’s bullish AI-driven guidance and Q4 outlook. Despite robust revenue forecasts and a growing data center footprint, broader sector jitters and valuation concerns kept the rally in check. The market seems to be saying, “Show me the margin, not just the hype.”
  • NVIDIA (NVDA, $186.86, -3.58%): The chipmaker’s stock faced headwinds, joining the tech sell-off as rate-cut expectations cooled. While AI remains the golden goose, investors are now asking if the goose can keep laying eggs at the same pace.
  • Broadcom (AVGO, $339.98, -4.29%): The company’s recent foray into AI infrastructure continues to attract attention, though the sector’s volatility is a reminder that even the best diversification can’t fully insulate from a tech-wide correction.
  • Intel (INTC, $35.91, -5.23%): Intel’s shares were under pressure, reflecting ongoing challenges in the PC and semiconductor markets. The company’s turnaround efforts are still a work in progress, and investors remain skeptical about its ability to reclaim its former glory.
  • Oracle (ORCL): Oracle dropped 4.15% to $217.57, weighed down by sector-wide tech weakness. The company’s cloud and AI initiatives continue to be a bright spot, but the broader market’s risk-off mood has dimmed the shine for even the most established names.

Consumer & Industrial: Apple, Tesla, McDonald’s, Rio Tinto

  • Apple (AAPL): Apple’s stock followed the tech sector lower closing off .19% to $272.95 , with investors reassessing the company’s growth prospects amid a slowing global economy. The iPhone maker’s recent product launches have been well-received, but the market is now focused on the next big thing.
  • Tesla (TSLA): Tesla’s shares were volatile falling 6.64% to $401.99, reflecting the company’s ongoing challenges with production and competition. The stock’s wild swings are a reminder that in the EV market, the only constant is change.
  • McDonald’s (MCD): McDonald’s held up relatively well rising .21% to $307.58, with its defensive profile and steady cash flows providing a safe haven for investors. The company’s global footprint and brand strength continue to be a source of comfort in uncertain times.
  • Rio Tinto (RIO): Rio Tinto’s shares fell .10% to $71.04. The company’s diversified portfolio and strong balance sheet provide a buffer, but the sector’s fortunes are closely tied to global economic trends.

Communication & Software: Meta, Nokia, Palantir, Opendoor, OKLO

  • Meta (META): Meta’s stock rose +.14%, avoiding the broader tech sell-off. The company’s recent focus on AI and the metaverse continues to attract attention, but investors are now asking for more concrete results.
  • Nokia (NOK): Nokia’s shares fell 3.42% to $6.78, reflecting the company’s defensive profile and steady cash flows. The company’s focus on 5G and network infrastructure continues to be a source of strength.
  • Palantir (PLTR): Palantir’s stock was volatile falling 6.53% to $172.14, reflecting the company’s ongoing challenges with growth and profitability.
  • Opendoor (OPEN): Opendoor’s shares were under pressure falling 8.64% to $8.56 after yesterday’s double digit ascent, reflecting the ongoing challenges in the housing market. The company’s recent focus on technology and data analytics continues to attract attention, but the sector’s fortunes are closely tied to global economic trends,
  • OKLO (OKLO): OKLO’s stock fell 8.57% to $101.64

Health Care: Eli Lilly (LLY)

  • Eli Lilly (LLY): Eli Lilly’s stock toped $1k rising .50% to $,022.87 now up 32.50% YTD, driven by the company’s announcement of most-favored nation drug pricing for its weight-loss drugs. The move was well-received by investors, who see it as a sign of the company’s commitment to innovation and affordability.

Gold, Silver, and Bitcoin today


Gold: Closed at $4,157.50 per ounce, off .93%.
Silver: Silver fell 2.30% to $52.23/oz.​
Bitcoin: Fell below $100k down to the $8k range today off nearly 3%.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4795), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.34), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated, “These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.4690), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, reported (Nov. 13) its financial results for the quarter ended September 30, 2025, and provided a business update highlighting key corporate and clinical advancements across its vaccine and oncology programs. David Dodd, CEO of Geovax stated, “As highlighted in this report, during the third quarter GeoVax continued making important progress, advancing innovative vaccines and immunotherapies that address urgent and underserved medical needs. With continued global Mpox spread and constrained vaccine supply, our GEO-MVA program represents a U.S.-based, scalable, next-generation MVA platform. Our EMA and BARDA-aligned program position GeoVax to accelerate regulatory readiness and commercial entry. For our GEO-CM04S1 COVID-19 vaccine program, recent clinical presentations validate our belief that multi-antigen vaccines – expressing both spike and nucleocapsid – are essential for breadth and durability in vulnerable immunocompromised populations. In particular, the robust immune responses demonstrated in Chronic Lymphocytic Leukemia (CLL) patients represents a meaningful step forward in addressing the unmet needs of over 40 million immunocompromised Americans. In our Gedeptin(R) oncology program, the expansion into multiple solid tumor indications builds upon a growing recognition that tumor-targeted immune priming can dramatically improve checkpoint outcomes. We are executing a clear path to clinical and commercial value creation. GeoVax continues to execute with purpose and discipline. Our multi-antigen vaccine and immunotherapy platforms position the Company squarely within the national call to strengthen America’s health security, expand domestic manufacturing, and deliver equitable global solutions.”

Volato Group, Inc. (NYSE American: SOAR, $1.40) and M2i Global, Inc. (MTWO, $.0958) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $3.92) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s disease. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $34.01) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

  1. https://www.briefing.com/stock-market-update
  2. https://www.cnbc.com/2025/11/12/stock-market-today-live-updates.html
  3. https://www.reuters.com/business/us-futures-muted-traders-await-data-after-federal-reopen-2025-11-13/
  4. https://finance.yahoo.com/news/major-us-stock-indexes-fared-212100570.html
  5. https://www.bloomberg.com/news/articles/2025-11-12/stock-market-today-dow-s-p-live-updates
  6. https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-13-2025
  7. https://www.businessinsider.com/stock-market-today-government-shutdown-tech-stocks-tsla-pltr-nvda-2025-11
  8. https://www.cnn.com/2025/11/13/economy/us-stock-market
  9. https://www.investopedia.com/dow-jones-today-11132025-11848610
  10. https://www.briefing.com/stock-market-update
  11. https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-nasdaq-sink-as-wall-street-eyes-fallout-from-us-shutdown-232101043.html
  12. https://www.briefing.com
  13. https://finance.yahoo.com/video/dow-nasdaq-p-500-fall-211447011.html
  14. https://www.briefing.com/weekly-wrap

November 13, 2025

Shutdown Ends: How Washington’s Budget Deal Reshapes Markets and Airlines -( $SPY $QQQ $DIA )

A brisk wind swept through the newsroom, carrying whispers of relief, risk, and the soft clack of keyboards. Screens flashed tickers as traders recalibrated after the shutdown’s end, a concrete event that shifted sentiment more decisively than a surprise rate cut. The narrative now orbits around effects: the immediate quiet on timing risk, the longer arc of policy execution, and the recalibration across sectors that depend on steady budgets.

The End of the Pause, The Start of the Pulse

Congress and the White House wrapped a short-term funding agreement around a longer-term budget framework, ending the shutdown and erasing the most acute near-term default scare. But endings in Washington rarely come with a clean slate. The real effects show up in project timelines reset, grant approvals resumed, and a disciplined push to reallocate funds toward previously stalled goals. Markets breathed a measured sigh, recognizing both relief and the work ahead to translate resolved headlines into resolved outcomes.

Sector Ripples: Airlines to Tech

Airlines pivoted from crisis mode to capacity planning, reworking load factors, fare curves, and staffing forecasts. The immediate disruption premium began unwinding as schedules stabilized and visibility returned to demand. In tech and defense, contractors and suppliers recalibrated pipelines, accounting for re-baselined budgets and new procurement rhythms. The banking and financial-services ecosystem absorbed the repricing of risk and the return-to-workflow in government-tied portfolios, adjusting liquidity forecasts and capital allocation plans accordingly.

The Policy Afterglow

With the crisis officially closed, agencies launched execution sprints: finalizing appropriations, syncing project timelines, and tightening crisis-response playbooks. The immediate market reaction cooled into a more durable, data-driven rhythm. Investors watched for evidence that the end-of-shutdown momentum translates into faster project execution, improved cash flows, and clearer forward guidance across sectors.

Editorial Tempo

The desk kept a brisk, precise tempo, translating policy cadence into actionable insight. The relief from resolution blended with a sober focus on implementation risk: will the budget framework unlock productivity, or will oversight and bureaucratic friction reintroduce headwinds? The narrative shifted from drama to delivery, from headlines to outcomes.

The Market-Choreography Throughline

Ending the shutdown altered the tempo, not the tune. The first-order effect was relief and clarity; the second-order effects depend on how quickly agencies convert appropriations into tangible results. Investors examined sector-specific catalysts: infrastructure funding ramps, defense modernization plans, healthcare and science funding, and the cadence of permit and grant approvals.

The Takeaway

The shutdown’s end marks a milestone, not a verdict on future fiscal discipline. Markets rewarded clarity but remain vigilant about execution risk, reform momentum, and the speed with which policy becomes practice.

November 12, 2025

Waymo on the Freeway: A Robotaxi Milestone rattles the markets


Waymo’s latest milestone—rolling driverless robotaxis onto U.S. freeways across select markets—reads like a sector earnings beat in real time. The move expands utilization horizons, tests risk-adjusted margins, and tightens the link between autonomous software reliability and fleet economics. Investors are watching how freeway deployments shift unit economics, insurance costs, and capex pacing as Waymo scales from controlled corridors to highway-grade operations. In a market where cost of capital and safety credentials dominate the narrative, this milestone reframes the roadmap for autonomous mobility as a capital-light, utilization-driven growth story.

Milestone in the making


Waymo’s highway rollout marks a decisive shift from limited-testing regimes to commercial highway operations. The change means more miles per vehicle per day, potentially improving fleet-operator economics even as the upfront costs for sensors, redundancy, and software safeguards remain high. The market will scrutinize maintenance cycles, software update cadence, and safety incident data as the levers that determine whether higher utilization translates into durable profitability or pressure on operating expenses. The broader arc includes regulatory navigation and the competitive dynamics with other autonomy developers, where speed to safe, scalable highway driving can become a meaningful differentiator.

Economic implications for investors

  • Fleet utilization and capex: Higher miles per vehicle can amortize fixed costs more quickly, but the drag of high-surity hardware and safety systems requires careful capital planning and amortization assumptions. Market pricing for robotaxi rides, insurance models, and maintenance will shape the long-run margin profile.
  • Insurance and risk management: Lower accident rates and advanced safety protocols can reduce premiums and claims costs over time, potentially unlocking favorable loss ratios as the software stack proves its reliability at scale.
  • Competitive landscape: Waymo’s execution on highways could set a de facto standard, influencing investor expectations for speed of deployment, regulatory approvals, and partnership opportunities in logistics and urban mobility ecosystems.
  • Revenue model evolution: The highway expansion could accelerate volume growth and open up new service variants, such as airport access, last-mile mobility bundles, and fleet-management software services for operators.

Operational and regulatory context


The highway-enabled service operates within a complex regulatory backdrop that includes state-by-state permitting, safety audits, and ongoing evaluations of risk in high-speed environments. Successful rollout requires not just technical reliability but disciplined execution around rider opt-ins, safety documentation, and incident reporting. Competitive differentiation will likely hinge on the robustness of the software stack, the depth of safety assurances, and the pace at which Waymo can extend highway access to additional markets without compromising the risk profile.

What this means for the future of mobility markets


If the freeway-capable robotaxi model proves scalable and profitable, broader mobility ecosystems could recalibrate investment priorities across AI software platforms, sensor suppliers, and autonomous-vehicle fleets. The potential spillovers into logistics, remote fleet monitoring, and insurance-linked services could broaden the addressable markets for AI-first mobility solutions. In short, the freeway milestone adds a tangible data point to a larger narrative: autonomous driving is moving from a laboratory experiment to a market-validated business model.

The Sources

  1. https://en.wikipedia.org/wiki/Waymo
  2. https://www.insurancejournal.com/news/national/2025/11/12/847254.htm
  3. https://teslanorth.com/2025/11/12/waymo-robotaxis-now-driving-on-freeways-and-to-airports/
  4. https://www.insurancejournal.com/news/west/2025/11/12/847243.htm
  5. https://www.ttnews.com/articles/waymo-robotaxis-freeways-first-us
  6. https://hoodline.com/2025/01/waymo-launches-testing-of-driverless-robotaxis-on-los-angeles-freeways-expanding-autonomous-reach/
  7. https://www.benzinga.com/news/25/11/48808971/waymo-launches-driverless-robotaxis-on-freeways-in-first-for-us-bloomberg
  8. https://en.wikipedia.org/wiki/Robotaxi
  9. https://www.azcentral.com/story/money/business/tech/2025/11/12/waymo-phoenix-freeways/87150109007/
November 12, 2025

DJIA Eclipses Record 48K As AMD & Opendoor Soar – Wed., Nov. 12, 2025 -( $AMD $EPRX $GOVX $INTC $MCD $NOK $NVDA $OKLO $OPEN $RIO $SOAR Rise!)

The major indices closed with a mixed tone after a session of careful balance between safety in value plays and the still-ambitious tilt toward growth. The S&P 500 eked out a gain, the Dow inched into positive territory as fresh macro cues rattled around, while the Nasdaq and Russell faced a modest pullback as investors recalibrated holdings in technology and growth names. The day’s price action underscored the ongoing tension between the resilience of the domestic economy and the wobble in high-duration tech multiples as traders digest inflation dynamics and central-bank chatter.

Macro and markets

  • S&P 500: Closed higher, up roughly 0.6% to 6,850.92, continuing a pattern of narrow daily ranges as investors weigh earnings signals against macro uncertainty. The index’s breadth remained modest, with leadership rotating between financials and select consumer-staples versus some laggards in high-growth tech.
  • Dow Jones Industrial Average: Finished in positive territory, registering a .68% gain to 48,254.82 and cresting the 48,000 level for the first time in today’s session’s intraday action. The cohort of bellwethers leaned toward industrials and select energy stocks amid inflation-watch narratives.
  • Nasdaq Composite and Russell indices: The Nasdaq retreated modestly off .26% to 23,406.46, pressured by a handful of heavyweight tech components whose softness outweighed pockets of strength elsewhere. The Russell 2000 also softened by .30% to 2,450.80, underscoring continued caution around mid- and small-cap risk assets amid higher-for-longer rate expectations.
  • Interest rates and yield curve: The yield environment remained influenced by ongoing expectations of the Federal Reserve’s policy path, with the 2-yr falling to 3.576% and the 10-yr falling to 4.069%.
  • Tariffs and trade: Today’s tariff chatter and policy signals kept market participants cautious about near-term import-position shifts, with some rotation into defensive sectors as a hedge against policy surprises.

Key corporate moves and notable names

  • AMD, NVIDIA, Intel (INTC, $37.89, +.03%): The semiconductor names remained in focus as investors weighed demand signals for GPUs and data-center accelerators against supply- and execution-related risk. NVIDIA’s (NVDA, $193.80, +.33%) and AMD’s (AMD, $258.89, +9%) momentum drivers remained tied to AI deployment cycles, enterprise demand, and any incremental guidance on production ramp and pricing discipline. Intel faced cautious positioning as investors awaited incremental semiconductor-capacity signaling and product progress updates.
  • Apple and Tesla: Apple’s ecosystem resilience and services growth continued to anchor the mega-cap narrative, while Tesla’s volatility persisted as the EV megatrend remains a focal point for both valuation and margin commentary. Both names drew attention to supply-chain normalization and demand in key geographies.
  • Broadcom (AVGO, $355.22, +.93%), Nokia ($7.02, +1.74%), McDonald’s (MCD, $306.94, +.04%), Oracle, Palantir, Meta, OKLO (OKLO, $111.17, +6.67%), Opendoor ($9.37, +10.50%), Rio Tinto Group (RIO, $71.11, +1.12%): Broadcom and Oracle continued to be barometers for enterprise technology demand and data infrastructure spend; Palantir and Meta rotated in and out of leadership groups as sentiment on AI exposure and online advertising cycles evolved. Nokia’s mobile/5G positioning faced competitive pressures. Rio Tinto and OKLO (nuclear-related) drew interest for sector-specific catalysts, while Opendoor’s housing-related equity trajectory remained sensitive to mortgage rates and housing demand. McDonald’s continued to reflect global consumer resilience in a mixed-cost environment, with currency effects and unit growth dynamics in focus.
  • Crypto and commodities: Gold ($4,202.40, +2.09%) and silver ($53.345, +5.13%) traded with a premium on risk-off sentiment in spurts, while oil fell 4.39% to $58.36 on global demand cues and inventory dynamics. Bitcoin pulled back ~.96% to $101,970.

What to watch next

  • FOMC and policy expectations: Markets continue to parse the timing and magnitude of potential rate adjustments, with investors awaiting any new summaries, dot plots, or communications from the Federal Reserve that could inform the next moves in the rate cycle and the tempo of balance-sheet normalization.
  • Inflation and macro data: Ongoing inflation data, labor market signals, and consumer demand indicators will be critical in shaping bets on timing for rate changes and the resilience of the earnings cycle across sectors, but the hopefully soon to tend U.S. shutdown is still delayingreports to be created.
  • Sector rotation drivers: Expect continued dispersion within technology versus value-oriented sectors, with AI-related demand, enterprise capex, and consumer demand remaining the principal determinants of near-term leadership in the indices.

Closing Macro Thought


In a market environment calibrated for the next policy signal and corporate earnings cadence, investors are favoring high-quality cash-generative franchises with clear secular tailwinds and pragmatic guidance. The day’s moves reflect a market that is discerning, not desperate, about growth winners while preserving capital in what remains a landscape of complexity and opportunity in equal measure.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4830), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.60, +1.07%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 4) its financial results for the third quarter of 2025 and provided a business update. Dr. James Helliwell, Chief Executive Officer of Eupraxia stated, “The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE). Our highest-dose cohort delivered the largest improvements in tissue health outcomes and eosinophil reduction observed to date, with no additional safety concerns. Coupled with the successful completion of our $80.5 million financing supported by strong life-science focused investors, we are now well resourced to advance the EP-104GI program, including through topline data from the Phase 2b RESOLVE Trial expected in the third quarter of 2026.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.4979, +.38%), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced that it will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on Thursday, November 13, 2025. Following the release, management will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update.

Volato Group, Inc. (NYSE American: SOAR, $1.42, +2.90%) and M2i Global, Inc. (MTWO, 10, +8.58%) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $4.02) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s disease. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $37.) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

  1. https://finance.yahoo.com/news/stock-market-news-nov-12-144600218.html
  2. https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-12-2025
  3. https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-circle-crcl-oklo/
  4. https://finance.yahoo.com/quote/%5EGSPC/history/
  5. https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-11-2025
  6. https://archive.org/stream/InternationalHeraldTribune1969FranceEnglish/Nov%2016%201969,%20International%20Herald%20Tribune,%20%2335370,%20France%20(en)_djvu.txt
  7. https://www.reuters.com/world/china/global-markets-global-markets-2025-11-12/
  8. https://www.worldradiohistory.com/Archive-All-Music/Archive-RandR/2000s/2004/RR-2004-01-23.pdf
  9. https://www.financialjourney.com/campaigns/monthly-market-insights
  10. http://www.hongik-art.com/redboard/redboard.asp?tn=artinfo&key_id=1063&b_no=517&page=7&category=0&searchword=&orderby_1=No&orderby_2=Desc
  11. https://www.nasdaq.com/articles/house-vote-government-re-opening
  12. https://www.wsj.com/public/resources/documents/QWFbwbEWyywuj2tMgcsA-WSJNewsPaper-5-3-2025.pdf
  13. https://www.wsj.com/public/resources/documents/SskW9BECxkxudA2Y6ZCC-WSJNewsPaper-9-7-2024.pdf
  14. https://ufdcimages.uflib.ufl.edu/AA/00/06/85/31/01806/2024-08-04.pdf
  15. http://web.conradreynolds.com/trib/2019-05-22.pdf
  16. https://www.scribd.com/document/99078434/Times-Leader-07-04-2012
  17. https://www.egrouppartners.com/wp-content/uploads/2021/04/THE-BOOK-Complete-version.pdf
November 12, 2025

Can Centessa’s $250M Equity Windfall Transform Sleep Disorder Treatments? -( $CNTA $IBB $XBI )

Centessa Pharmaceuticals made waves in biotech finance this week by pricing its $250 million public offering at $21.50 per American Depositary Share (ADS)—a move that sent investors and industry watchers scrambling for their calculators and a fresh cup of clinical optimism.

Raising Capital: Wall Street Style

Centessa is issuing 11,627,907 ADSs, representing a healthy slice of its share pie, and even threw in a 30-day option for underwriters to pick up another 1,744,186 ADSs, just in case anyone arrived at the party late but still wanted dessert. The offering is slated to close around November 14, provided Wall Street’s usual litany of closing conditions don’t steal the show. Managing the syndicate are Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities—the investment banking equivalent of a red-carpet ensemble for any biotech bash.

Battle for Brainpower: Clinical Focus and Competition

All proceeds—after Wall Street shaves off its customary slice in fees and commissions—will be fueling Centessa’s ambitious plans to accelerate clinical trials in neurological disorders, especially its OX2R agonist program for narcolepsy and other sleep maladies. The company hopes this cash infusion, combined with a $349 million cash reserve, will keep the lights on and the pipettes working through mid-2027, a timeline that’s bold even for biotech standards. Just don’t mention net losses ($54.9 million for Q3)—in biotech, that’s less a scarlet letter and more like a badge of honor at the exploratory stage.

Investor Sentiment: Optimism With a Wink

Wall Street’s response: clear positive signals. Shares lifted following the announcement, proof investors are betting Centessa’s neuroscience pipeline might just redefine how the world sleeps, thinks, and perhaps dreams of future profits. Institutional investors, bolstered by top-tier underwriters, are signaling their confidence in Centessa like seasoned poker players who may have just glimpsed the ace in their hand. The deal’s structure also suggests management is keen to minimize “further dilution in the near term”—an attempt to keep loyal shareholders from seeing their stakes vanish like a dream before morning coffee.

Strategic Implications: Brains, Bucks, and Wit

Centessa’s move is more than just another biotech cash grab. It’s a strategic dance—aligning capital with critical scientific milestones, embracing risk, and balancing investor enthusiasm with the realities of regulatory mazes and competitive pressure from rivals like Alkermes and Takeda. As the company pursues registrational studies for its narcolepsy candidate, the street will watch closely to see if scientific promise can be translated into commercial reality and, in time, shareholder returns (or at least an interesting story for the next earnings call)..

In summary: Centessa’s $250 million public offering is a masterclass in biotech bravado, Wall Street showmanship, and scientific ambition—a tale fit for the front page, best paired with a strong espresso and a pinch of sophisticated humor.

The Sources

  1. https://finance.yahoo.com/news/centessa-pharmaceuticals-announces-pricing-250-014000007.html
  2. https://stocktitan.net/news/CNTA/centessa-pharmaceuticals-nasdaq-cnta-prices-250m-ads-offering-1163m-ads-o4bdwqinw8sl.html
  3. https://seekingalpha.com/news/4110845-centessa-pharmaceuticals-prices-250m-offering-at-usd21_5-per-ads-cnta-nasdaq
  4. https://www.investing.com/news/stock-market-news/centessa-prices-public-offering-of-116-million-adss-at-2150-each-3426054
  5. https://www.gurufocus.com/news/2490836/centessa-pharmaceuticals-cnta-launches-250m-public-offering
  6. https://www.marketscreener.com/quote/stock/CENTESSA-PHARMACEUTICALS-PLC-122366697/news/Centessa-Pharmaceuticals-Shares-Rise-After-Pricing-250-Million-American-Depositary-Share-Offering-45450435/
  7. https://www.nasdaq.com/articles/centessa-pharmaceuticals-prices-public-offering-at-$21.50-per-ads
  8. https://ainvest.com/centessa-pharmaceuticals-250m-equity-raise-strategic-capital
  9. https://www.quiverquant.com/news/CNTA/Centessa%20Pharmaceuticals%20plc%20Announces%20Underwritten%20Public%20Offering
  10. https://www.clinicaltrialsarena.com/analysis/narcolepsy-race-alkermes-ox2r-nt2-centessa/

Your Guide To Staying Informed In The Markets

Subscribe For Free Email Updates Access To Exclusive Research

Vista Partners — © 2026 — Vista Partners LLC (“Vista”) is a Registered Investment Advisor in the State of California. Vista is not licensed as a broker, broker-dealer, market maker, investment banker, or underwriter in any jurisdiction. By viewing this website and all of its pages, you agree to our terms. Read the full disclaimer here

Copyright © 2026 Vista Partners, LLC. All rights reserved